Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A02845-50 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Antiphospholipid syndrome (APLS) is a rare pathology characterized by the association of thrombotic (arterial, venous) or obstetric clinical manifestations and the persistent presence at least twelve weeks apart of antiphospholipid antibodies (APL). It is also accompanied by accelerated atherosclerosis responsible for an increased incidence of myocardial infarction, peripheral arterial disease and stroke explaining the high cardiovascular morbidity and mortality of these patients. APS can be isolated (primary) or integrated into an autoimmune pathology such as systemic lupus erythematosus (SLE), thus defining secondary APS. Current treatment is based on anticoagulation. Currently, epidemiological data that have evaluated recurrences have estimated a rate of 5% per year. However, these studies are old and due to the significant heterogeneity of patients included in this registry, it seems that these figures are not in agreement with clinical reality.
Furthermore, several new therapeutic developments have emerged in the field of anticoagulation with the marketing of DOACs, making the EUROPHOSPHOLIPIDE data questionable. Currently, there are no clinical studies to justify the use of DOACs in this indication, but several patients have received these drugs due to intolerance or refusal of vitamin K antagonists. The other therapeutic innovation compared to the data from the EUROPHOSPHOLIPIDE cohort is the increasing use of hydroxychloroquine in clinical practice in patients with primary APS. A trial (APLAQUINE) is currently underway in our department which aims to study the endothelial protective effect of this treatment in patients with primary APS.
This trial is a retrospective and prospective cohort epidemiological study whose primary objective is to determine the rate of thrombotic recurrence in our center. Secondary objectives are to determine the risk factors associated with recurrence, assess the safety of long-term treatment in this population, and evaluate the overall morbidity and mortality of this rare disease.
A better understanding of thrombotic recurrence is essential to calculate realistic population sizes for future therapeutic trials.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006 | Other | The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population. |
| Measure | Description | Time Frame |
|---|---|---|
| Thrombotic recurrence rate | The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department. | Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease. |
| Measure | Description | Time Frame |
|---|---|---|
| Complication rate | Evaluate the complication rate associated with treatment | Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease. |
| Risk factors associated |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients monitored for Antiphospholipid Syndrome (APLS) in the internal medicine department
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sébastien SM MIRANDA, Doctor | Contact | 02 32 88 90 01 | +33 | Sebastien.Miranda@chu-rouen.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University hospital of Rouen | Recruiting | Rouen | 76031 | France |
The data provided will be the property of the sponsor and will be used solely for its own research activities.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016736 | Antiphospholipid Syndrome |
| ID | Term |
|---|---|
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
A collection of biological samples will be created during this research protocol to enable the subsequent identification of endothelial, oxidative stress and coagulation parameters in these patients.
Look for risk factors associated with thrombotic recurrence |
| Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease. |
| Mortality rates | Evaluate the mortality rates of this patient population | Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease. |
| Morbidity rates | Evaluate the morbidity rates of this patient population | Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease. |